IFLR1000

Merck & Co €464 million acquisition of Rigontec

6/9/2017
Private acquisition
Select tab

€ 464 million

$ 555 million

Announced

6/9/2017

Overview:

  • US pharmaceutical group Merck & Co has agreed a deal to acquire Rigontec for fee which could rise to €464 million.
  • Rigontec is a Munich based bio-tech company which manufactures cancer treatment drugs.
  • Merck will pay an initial €115 million for Rigontec. The remainder of the fee is dependent on the business meeting certain targets. 

Katrin Kostadinova - Data analyst 

Jurisdiction:

Germany

Deal type:

Private acquisition

Practice area:

M&A

Governing law:

Germany

Industry sector:

Pharmaceuticals and life sciences

Firms:
Dechert

Party: Rigontec (Target)

Paul Hastings

Party: Merck & Co (Acquirer)

Lawyers: Christian Mock (left the firm), Regina Engelstaedter

POELLATH

Party: Rigontec (Management)

Lawyer: Michael Inhester

Related deals